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Background: We studied to what extent the level of scientific knowledge on exceptionally rare metabolic inherited
diseases and their potential orphan medicinal products is associated with sponsors deciding to apply for an orphan
designation at the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Methods: All metabolic diseases with a genetic cause and prevalence of less than 10 patients per 1 million of the
population were selected from the ‘Orphanet database of Rare diseases’. The outcome of interest was the
application for an orphan designation at FDA or EMA. The level of publicly available knowledge of the disease and
drug candidate before an orphan designation application was defined as whether the physiological function
corresponding with the pathologic gene and initiation of the pathophysiological pathway was known, whether an
appropriate animal study was identified for the disease, whether preclinical proof of concept was ascertained and
the availability of data in humans. Other determinants included in the study were metabolic disease class, the
prevalence of the disease, prognosis and time of first description of the disease in the literature. Univariate relative
risks (RRs) and 95% confidence intervals (CIs) of an orphan designation application were calculated for each of
these determinants. In addition, a multivariate Cox regression analysis was conducted (Forward LR).
Results: In total, 166 rare metabolic genetic diseases were identified and included in the analysis. For only 42 (25%)
of the diseases an orphan designation application was submitted at either FDA or EMA before January 2012. The
multivariate analysis identified preclinical proof of concept of a potential medicinal product as major knowledge
related determinant associated with an orphan designation application (RRadj 3.9, 95% CI 1.9-8.3) and confirmed
that prevalence of the disease is also associated with filing an application for an orphan designation (RRadj 2.8, 95%
CI 1.4-5.4).
Conclusion: For only one out of four known exceptionally rare metabolic inherited diseases sponsors applied for
an orphan designation at FDA or EMA. These applications were found to be associated with the prevalence of the
rare disease and the level of available scientific knowledge on the proof of concept linking possible drug
candidates to the disease of interest.
Keywords: Rare disease, Orphan medicinal product, Inherited metabolic disease, Prevalence, Preclinical proof
of concept* Correspondence: a.k.mantel@uu.nl
1Utrecht Institute for Pharmaceutical Sciences, Division of
Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, P.O.
Box 80 082, 3508TB Utrecht, The Netherlands
Full list of author information is available at the end of the article
© 2013 Putzeist et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Putzeist et al. Orphanet Journal of Rare Diseases 2013, 8:179 Page 2 of 9
http://www.ojrd.com/content/8/1/179Introduction
Rare diseases are a complex and heterogeneous mosaic
of an estimated 6000–8000 conditions. Several jurisdictions,
including the US and the EU, have successfully introduced
specific legislation with a number of (economic) incentives
(see Table 1) that stimulate the development of products
for rare diseases [1-4]. In the first 25 years of the Orphan
Drug Act in the US 1892 products have been designated as
orphan, and 326 products have been approved [5]. These
326 products target more than 200 rare diseases and
represent a difference in the lives of millions of rare
disease patients. In the EU, in the first decade more than
850 orphan drug designations have been granted by the
European Commission and more than 60 orphan drugs
have received marketing authorization [6].
Despite this success, it is important to understand that
the majority of the estimated 6000–8000 rare diseases
has a prevalence of less than 10 patients per 1 million
inhabitants (less than 5000 patients in the EU) [7]. The
risk exists that such a small number of patients and
consequently small market size make it less attractive
for the pharmaceutical industry to invest in the develop-
ment of therapies for low prevalence rare diseases.
Heemstra et al. and Yin et al. showed that translation of
rare disease research into an orphan drug development
program is more likely for a more prevalent rare disease
than a less prevalent rare disease [8,9]. However, a recent
overview by the FDA clearly revealed that orphan medi-
cinal products approved for low prevalence rare diseases
are certainly not uncommon [5]. An example of an autho-
rized product to treat a low prevalence rare metabolic
disease is idursulfase (Elaprase®), an enzyme replacement
therapy to treat Hunter syndrome also known as mucopo-
lysaccharidosis Type II [10]. Hunter syndrome is a very
rare genetic life-threatening lysosomal storage disease
characterized by the accumulation of glycosaminoglycans
due to the deficiency of the enzyme iduronate-2-sulfataseTable 1 Orphan designation criteria at EMA and FDA
Orphan designation criteria
European Medicines Agency
(i) The medicine should be intended for the diagnosis, prevention or
treatment of a life-threatening or chronically debilitating disease,
affecting a maximum of 500 in 1 million people in the EU;
(ii) It must be unlikely that the revenue after marketing authorisation
will cover the investments in its development;
(iii) No satisfactory treatment for the disease exists or the new
medicinal product is of significant benefit to the patients;
(iv) An application for an orphan designation should explain the medical
rationale of the medicinal product by means of the mechanism of
action as far as it’s known, and some preclinical or clinical date are
‘generally’ required, including all published references [3].[10,11]. Apart from idursulfase, other marketed products
for low prevalence rare metabolic diseases are for example
nitisinone (Orfadin® for Tyrosinemia type I) and carglumic
acid (Carbaglu® for N -acetylglutamate synthetase (NAGS)
deficiency).
Apparently, drug development for low prevalence rare
disorders may be less obvious, perhaps challenging, but
certainly not impossible. Considering that the majority
of low prevalence rare diseases remain without therapy
[6,8], increased knowledge of the underlying transla-
tional process provides better input for novel approaches
to improve orphan drug development. Heemstra et al.
showed that disease-specific scientific output was a pre-
dictive factor for successful translation of rare disease
research into an orphan drug development program [8].
However, the authors did not differentiate between
different research areas such as disease etiology and
pathophysiology, availability of suitable animal models
and/or (pre-) clinical proof of concept studies. There-
fore, we studied to what extent disease characteristics as
well as the level of publicly available scientific knowledge
on low prevalence rare metabolic diseases and its poten-
tial medicinal products is associated with a sponsor’s
decision to apply for an orphan designation at FDA
or EMA.
Methods
All rare metabolic diseases (inborn errors of metabolism)
were downloaded from the ‘Orphanet database of Rare
diseases’ on 17 January 2012 [12]. Subsequently, diseases
with a prevalence of less than 10 patients per 1 million
of the population and for which a genetic cause has been
established (heritance known) were extracted from the
dataset and included in the study (N = 166). The
outcome of interest for this study was the first orphan
designation application at the FDA or EMA. In case of
multiple orphan designation applications for the sameFood and Drug Administration
(i) The medicine should be intended for a disease or condition that
affects fewer than 200,000 people in the United States or, if the drug
is a vaccine, diagnostic drug, or preventive drug, the persons to
whom the drug will be administered in the United States are fewer
than 200,000 per year;
(ii) There is no reasonable expectation that costs of research and
development of the drug for the indication can be recovered by
sales of the drug in the United States;
(iii) An application for an orphan designation should contain the reasons
why such therapy is needed, accompanied by a discussion of the
scientific rationale for the use of the drug for the rare disease,
including all data from nonclinical laboratory studies, clinical
investigations, and other relevant data that are available to the
sponsor, whether positive, negative, or inconclusive. Copies of
pertinent unpublished and published papers are also required [4].
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selected the first application as a proxy for the intention
to initiate the development of a drug for the rare disease
leading to marketing authorization [13,14].
Determinants that described the level of available scien-
tific knowledge of the disease before the first orphan des-
ignation application were: (1) whether the gene function
corresponding with the pathologic gene and initiation of
the pathophysiological pathway was identified (yes, no)
and (2) whether an appropriate animal model was avail-
able for the disease (yes, no). Scientific knowledge related
to drug candidates was (3) preclinical proof of concept of
any drug candidate either in vitro or in an animal model
of the disease and (4) the availability of data in humans.
The availability of data in humans was defined as any clin-
ical testing of a drug candidate in patients with the rare
disease, irrespective of the type of treatment (symptomatic
or curative), the underlying study (a case report or a com-
parative study), whether the treatment was successful or
not, and - in case of the diseases for which an orphan
designation was available- irrespective of whether the
drug described was the drug of the orphan designation
application.
Data about the gene function and proteins or organ-
elles involved in initiating the pathophysiological path-
way and the availability of an appropriate animal model
were identified from the OMIM database of genetic dis-
eases [15]. Pubmed publications were the data source
for the animal model (additional to OMIM), preclinical
proof of concept and the availability of clinical data. All
Pubmed publications for each disease were identified by
Pubmed search strings according to Heemstra et al. [8],
taking into account all available synonyms for the dis-
ease and the date of the orphan designation application
(for diseases with an orphan designation) or the cut-off
date 01-01-2012 (for the diseases without orphan designa-
tion) [16]. The availability of clinical studies was verified at
clinicaltrial.gov [17].
Other determinants that were studied were the meta-
bolic disease class according to the Orphanet classifica-
tion, the prevalence of the disease (<1 per 1 million of
population or 1–9 per 1 million of population) and the
prognosis of the disease (fatal/chronically debilitating or
non fatal/not chronically debilitating). Besides, the period
in which the disease was first described (before 1977 or
starting from 1977) was assessed to study the association
with time.
The disease class, prognosis and prevalence were all
collected from Orphanet, as indicated in July 2012 [18].
In case of multiple prognoses depending on disease
severity, the worst prognosis was included. The year in
which the disease was first described in the scientific
literature was derived from OMIM [17]. For ten diseases
OMIM did not mention the year the disease was firstdescribed, and consequently another public source of
information (Pubmed and other public references) was
used to retrieve the data.
Univariate relative risks (RRs) of applying for an orphan
designation and 95% confidence intervals (CIs) were calcu-
lated for each of these determinants. In addition, a multi-
variate Cox regression analysis was conducted (Forward
LR) to obtain adjusted relative risks (RRadj). All analyses
were done using SPSS, version 19.0. The most recent year
that a rare inherited metabolic disease with an orphan
designation was first described was 1997. Absence of an
orphan designation for diseases first described after 1997
may be due to insufficient time to translate fundamental
disease knowledge into sufficient (pre-)clinical data requi-
red for the application of an orphan designation. Therefore,
a sensitivity analysis was performed in which all diseases
that were first described after 1997 were excluded.
Results
In total 166 metabolic genetic diseases with a prevalence
of less than 10 per 1 million patients were identified
from the Orphanet database of Rare diseases. Table 2
provides the Orphanet classification of these diseases
[18]. This table shows that three metabolic disease sub-
classes, i.e. lysosomal diseases (subclass of Metabolic dis-
eases involving complex molecules), protein metabolism
disorders (subclass of Metabolic Intoxication diseases)
and mitochondrial disorders (subclass of Energy metab-
olism disorders) represented more than half of the study
diseases (N = 91). The other inherited metabolic diseases
were a heterogenous group of disorders.
For 42 (25%) of the diseases at least one orphan designa-
tion application was submitted at either FDA or EMA,
whereas for the remaining 124 (75%) diseases such an
orphan designation application was not submitted before
January 2012. Figure 1 depicts the 42 orphan designations
applications over time. After 2000 there was an increase
in the number of orphan designation applications which
became even larger from 2006 onwards. The figure also
shows when low prevalence rare metabolic diseases with
an orphan designation were first described in the scientific
literature. Diseases with a long history, first described in
the scientific literature before 1960, were still well repre-
sented among the orphan designation applications in
2011. First orphan designation applications for relatively
new diseases, described after 1983, were submitted from
2006 onwards. A bibliometric analysis of the 166 low
prevalence rare metabolic diseases showed a clear differ-
ence between the group of low prevalence rare metabolic
diseases with an orphan designation and the group of
diseases without an orphan designation. More than 50%
(N = 23) of the 42 diseases with an orphan designation
application had a scientific output of more than 200
scientific papers. By contrast, only 9% (N = 11) of the 124
Figure 1 Number of first applications for an orphan designation at FDA or EMA over time and according to the period in which the
exceptionally rare metabolic inherited diseases were first described.
Table 2 Classification of exceptionally rare diseases included in the present study according to Orphanet
General classification Total (N = 166) Disease group classification Total
Metabolic disease involving complex molecules 62 Lysosomal diseases 31 (50%)
Purine or pyrimidine metabolism disorder 10 (16%)
Sterol metabolism disorder 8 (13%)
Metabolic neurotransmission anomaly 5 (8%)
Peroxisomal disease 4 (6%)
Metal transport or utilisation disorder 3 (5%)
Protein glycosylation disorder 1 (2%)
Metabolic intoxication disease 36 Amino or protein metabolism disorder 34 (94%)
Hyperoxaluria 1 (3%)
Methylmalonic aciduria - microcephaly - cataract 1 (3%)
Energy metabolism disorder 45 Mitochondrial disorder 26 (58%)
Fatty acid oxidation or ketogenesis disorder 7 (9%)
Creatine biosynthesis disorder 2 (4%)
Ketolysis disorder 2 (4%)
Enolase deficiency 1 (2%)
Gluconeogenesis disorder 1 (2%)
Hemolytic anemia due to glucophosphate isomerase deficiency 1 (2%)
Phosphoglycerate kinase 1 deficiency 1 (2%)
Pyruvate metabolism disorder 1 (2%)
Thiamine-responsive megaloblastic anemia syndrome 1 (2%)
Tricarboxylic acid cycle disorder 1 (2%)
Triose phosphate-isomerase deficiency 1 (2%)
Carbohydrate metabolism disorder 12 Glycogen storage disease 7 (58%)
Glucose transport disorder 4 (33%)
Familial hyperinsulinism 1 (8%)
Other metabolic disease 11 Metabolic disease associated with a progressive neurological disorder 6 (55%)
Miscellanous metabolic disease with mostly hepatic presentation 4 (36%)
Hereditary hypercarotenemia and vitamin A deficiency 1 (9%)
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scientific output of more than 200 scientific papers.
Table 3 demonstrates the univariate relative risks (RR)
of submitting an orphan designation application at FDA
or EMA for different disease characteristics and type/
level of publicly available scientific knowledge. Consider-
ing the level of scientific knowledge preclinical proof of
concept of drug candidates had the largest univariate RR
of an orphan designation application (RR 6.0 (95% CI
3.0-12.0)). The availability of data in humans (RR 3.3
(95% CI 1.7-6.6)) and the availability of an animal model
(RR 3.0 (95% CI 1.5-6.0)) also demonstrated a positive
association with the likelihood that a sponsor had filed
an orphan designation application. A similar, but not
significant, association was found for the identification
of the gene function and the underlying cause of the
disease (RR 26.1 (95% CI 0.7-966)). For none of the 26Table 3 Univariate relative risks of an orphan designation ap
characteristics and for publicly available scientific knowledge
Disease characteristics Total N = 166 OD app
1. Metabolic disease class
Metabolic disease involving complex molecules 62
Metabolic intoxication disease 36
Energy metabolism disorder 45
Carbohydrate metabolism disorder 12
Other metabolic disease 11







Fatal/chronically debilitating despite treatment 96
Non fatal/not chronically debilitating 61
Unknown 9
Scientific knowledge related variables
5. Gene function identified?
Yes 140
No 26
6. Animal model available?
Yes 87
No 79
7. Preclinical proof of concept?
Yes 53
No 113
8. In humans data available?
Yes 76
No 90diseases for which the gene function was not yet fully
identified an orphan designation application was sub-
mitted. Ten out of these 26 diseases were mitochondrial
diseases (subclass of energy metabolism disorders), which
suggests that for this disease group the pathophysiological
pathway requires further elucidation.
The metabolic diseases involving complex molecules
and the metabolic intoxication diseases were similarly
associated with orphan designation applications, whereas
the energy and carbohydrate metabolism disorders were
less likely to have an orphan designation application
(RR = 0.2 (95% CI 0.1-0.6) as compared to metabolic
diseases involving complex molecules). The positive
associations with an orphan designation application for
metabolic diseases involving complex molecules and
metabolic intoxication diseases were mainly driven by lyso-
somal (storage) diseases and amino or protein metabolismplication at EMA or FDA for different disease
lication N = 42 No OD application N = 124 Univariate RR (95% CI)
23 (37%) 39 (63%) Ref
14 (38%) 22 (61%) 1.1 (0.5–2.0)
3 (7%) 42 (93%) 0.2 (0.1–0.6)
1 (8%) 11 (92%) 0.2 (0.03–1.7)
1 (9%) 10 (91%) 0.3 (0.03–1.8)
36 (37%) 62 (63%) 4.2 (1.8–9.9)
6 (9%) 62 (91%) Ref
25 (66%) 13 (34%) 5.0 (2.7–9.2)
17 (13%) 111(87%) Ref
34 (35%) 62 (65%) 2.7 (1.3–5.8)
8 (13%) 53 (87%) Ref
0 (0%) 9 (100%) NA
42 (30%) 98 (70%) 26.1 (0.7–966)
0 (0%) 26(100%) Ref
33 (38%) 54 (62%) 3.0 (1.5–6.0)
9 (11%) 70 (89%) Ref
31 (58%) 22 (42%) 6.0 (3.0–12.0)
11 (10%) 102(90%) Ref
31 (40%) 45 (59%) 3.3 (1.7–6.6)
11 (12% 79 (88%) Ref
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eases and for 13 of 34 (38%) of amino or protein meta-
bolism disorders an orphan designation application was
submitted. Finally, a relatively high prevalence (1–9 per 1
million), poor disease prognosis and first description of the
disease ≤1977 were all positively associated with an orphan
designation application (Table 3).
The multivariate analysis (Table 4) confirmed a strong
association between the preclinical proof of concept of
potential medicinal products and applying for an orphan
designation (RRadj 3.9 95% CI 1.9-8.3) and also proved
that prevalence of the disease is associated with an orphan
designation application (RRadj2.8 95% CI 1.4-5.4). An add-
itional sensitivity analysis that excluded all diseases that
were first described after 1997 demonstrated only small
differences in (adjusted) RRs (data not shown).
Discussion
The majority of low prevalence rare diseases remain
without therapy, the development of medicines for such
diseases is considered an unmet medical need. This study
demonstrates the importance of mature scientific know-
ledge in the public domain for successful translation of
rare disease research into an orphan drug development
program, in line with Heemstra et al. [8]. The preclinical
proof of concept of a drug candidate and disease preva-
lence were identified as important factors driving sponsors
to apply for an orphan designation for a drug candidate.
The orphan designation application rather than designa-
tion approval was taken as study outcome, because we
were interested in the disease characteristics and level of
disease knowledge available at time of the initiative of
drug development for low prevalence rare metabolic
diseases. In practice all but one designation applications
were approved. Thus, our study also demonstrates the
association between the level of knowledge of the disease
and/or drug and granting orphan designations.
Knowledge of the disease
Our results demonstrate that for the majority of low
prevalence rare metabolic diseases included in the study
the causative gene and initiation of the pathophysiologicalTable 4 Multivariate relative risks of an application for an






1-9/1.000.000 5.0 (2.7–9.2) 2.8 (1.4–5.4)
<1/1.000.000 Ref Ref
Preclinical proof of concept?
Yes 6.0 (3.0–12.0) 3.9 (1.9–8.3)
No Ref Refpathway was known and that the diseases for which this
knowledge was lacking belonged to similar metabolic dis-
ease subclasses (e.g. mitochondrial diseases). Although
basic knowledge of the disease is generally considered a
prerequisite for further (pre)clinical drug development in
general [19,20], the elucidation of the gene function was
not identified as an independent driver for sponsors to
apply for an orphan designation. A total of 98 (70%) low
prevalence rare genetic metabolic diseases with an eluci-
dated gene function did not have an orphan designation.
Apparently, additional and more important reasons exist
that explain the observed lack of orphan drug development
for low prevalence rare metabolic diseases. First, elucida-
tion of the gene function is only one component of the elu-
cidation of the complete pathophysiological pathway from
gene (translation) to clinical symptoms and the identi-
fication of druggable targets. Secondly, even if extensive
disease knowledge is available this does not guarantee the
successful development of an orphan drug. For example,
cystic fibrosis, an inherited chronic disease that affects
70,000 people worldwide, has been studied extensively and
the pathophysiology is well known. However, the first
medicine to treat the underlying cause of cystic fibrosis,
ivacaftor (Kalydeco®) was only approved recently [21].
Still, pathophysiological knowledge of one disease
within a disease subclass may stimulate or act as catalyst
for disease research for other diseases within the same
subclass. For the mucopolysaccharidosis diseases (5 out
of 7 with an orphan designation) the underlying patho-
physiology is relatively well understood: a lack of specific
lysosomal enzymes leads to the degradation of glycos-
aminoglycans or mucopolysaccharides. The accumula-
tion of partially degraded glycosaminoglycans causes
interference with cell, tissue, and organ function causing
severe clinical symptoms [11]. Just like in the example of
idursulfase to treat Hunter syndrome or mucopolysac-
charidosis Type II, enzyme replacement therapies have
been developed as a response to enzyme deficiencies in
several other mucopolysaccharidosis diseases. Similarly
within the group of amino or protein metabolism disor-
ders all five urea cycle disorders, leading to ammonia
detoxification, received an orphan designation. The urea
cycle is well studied and several treatment strategies have
been developed such as drug suppletion therapies (argin-
ine therapy) or a druggable target such as circulating ni-
trogen (designated product glyceryl tri-(4-phenylbutyrate).
In addition, there is circumstantial evidence which
suggests that availability of a (potential) therapeutic mo-
dality for a specific rare disease appears to encourage rather
than discourage additional orphan drug development for
the same rare disorder [22]. As such crossing the transla-
tional chasm between research and development not only
represents the development of a potential life-saving or
quality of life-improving therapy for rare disease patients,
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ample, rare diseases share (parts of) the same biochemical
pathway, and consequently an orphan drug may be bene-
ficial for more than one disease. Nitisinone, a product
approved for tyrosinemia type I (Orfadin®) may also poten-
tially have a beneficial clinical effect for patients suffering
from alkaptonuria (AKU). The AKU society, a patient as-
sociation, is currently collaborating with academia and
industry to study the potential clinical effect of nitisinone
for AKU [23].
These examples underline that the availability of disease-
related knowledge in the public domain is crucial to initiate
an orphan drug development program by pharmaceutical
companies, but also increasingly by disease-focused foun-
dations [24].
Knowledge of the drug
Preclinical proof of concept of drug candidates was
identified as the major type of knowledge needed for an
orphan designation. According to our definition, preclin-
ical proof of concept was considered achieved in case of
a promising result in an in vitro or animal study with
any drug candidate studied in the target population, irre-
spective of the drug that was included in the orphan
designation application. To obtain an orphan designa-
tion a sponsor has to provide (pre-)clinical data that
confirm the medical plausibility of the intended drug
candidate [3,4]. Yet, for 40% of the metabolic diseases
for which proof of concept was demonstrated in a pre-
clinical study, an orphan designation was not applied
for. Possible explanation related to low prevalence are
the difficulties a sponsor may face during the subsequent
clinical development because of the extremely small
patient populations available for clinical research. Kakkis
et al. recently identified 15 inherited exceptionally rare
metabolic diseases with a relevant corresponding animal
model, a treatment with a known mode of action and a
clinically relevant treatment effect in animals but that
had stalled in clinical development. They demonstrated
the substantial potential benefit that surrogate endpoints
could offer to clinical drug development. The acceptance
of surrogate endpoints in clinical development of these
promising treatments would reduce the number of
patients needed for approval and may also persuade
sponsors to apply for an orphan designation [25].
In contrast to preclinical proof of concept, clinical
testing (data in humans) was only associated with an
application for an orphan designation in the univariate
analysis. This may be because of the way ‘data in humans’
were defined: as any treatment described in the scientific
literature, (i) either successful or not, (ii) either a case
report or a small trial and (iii) either a symptomatic or a
curative treatment. The thought behind this definition
was that (ad i) any drug developer could learn frompublished data about any drug treatment for the disease,
(ad ii) that requiring a clinical trial was not realistic for
low prevalence-rare diseases, and (ad iii) that orphan
designations can be applied for symptomatic treatments
as well as curative treatments.Other drivers for an orphan designation application
The dataset consisted of low prevalence rare metabolic
diseases (<10/million), the majority (N = 128; 77%) of
the diseases had a prevalence of less than 1 patient per
million inhabitants. Our study showed that diseases with
a prevalence of 1–9 per million had a higher chance of
an orphan designation application than diseases with a
prevalence of less than 1 per million. Our finding that
prevalence is an important factor that drives sponsors to
apply for an orphan designation is in line with previous
results by Heemstra et al. [8]. For some diseases less
than 20 cases have been described worldwide. Therefore,
a likely explanation for this finding is that a disease
prevalence of less than 1 per million is considered too
small by the pharmaceutical industry to invest in the
development of a therapy, despite the availability of
considerable disease knowledge, incentives offered by
the Orphan Regulation and opportunities for conditional
marketing approval and approval under exceptional cir-
cumstances in the EU [26,27]. The latter is best illus-
trated by the group of gamma-glutamyl cycle disorders
(N = 4, subclass of protein metabolism disorders), invol-
ved with the synthesis and degradation of glutathione.
At the time of our analysis only about ten patients were
described. Despite elucidation of the gamma-glutamyl
cycle, the genes and proteins involved and the availabil-
ity of knock-out mouse models no orphan designations
have been applied for by sponsors at the time of our
analysis.
Another explanation may be a lack of need of pharmaco-
logical treatment for some diseases, because either the
symptoms are not severe (e.g. hereditary hypercarotenemia
and vitamin A deficiency) or because other non-pharmaco-
logical treatments or life style changes are sufficient, such
as diet or exercise restrictions (e.g. for glucose-galactose
malabsorption) [28]. Third, medicinal products that are
already approved to the market can be prescribed off-label
to treat symptoms, e.g. anti-epileptics to treat convulsions
as a consequence of progressive neuronal damage of
McLeod neuroacanthocytosis syndrome [29] or vitamin
B12 injections for cobalamine deficiency disorders such as
Gräsbeck-Imerslund disease [30]. For these congenital
disorders the focus may be on care rather than on cure.
Finally, some metabolic diseases may be well treated by
suppletion of amino acids such as arginine or carnitine
(for some types of organic aciduria) or carbohydrates such
as glucose (for ketolysis disorders) [18].
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The methodology of our study has some limitations,
mainly related to potential discrepancies between the
availability of knowledge in scientific literature and the
knowledge referred to in the applications for orphan
designation. We studied whether the knowledge as avail-
able in scientific literature was an incentive to initiate
further research to the disease and drug candidates.
However, an orphan designation application can also be
based on unpublished studies, e.g. a preclinical proof of
concept study of the drug candidate only known to the
company or institution filing the application, but this
information is not available in the public domain and
could therefore not be included in the present study.
A limitation of this study is that the results do not
identify whether the drug described in a publication of
preclinical proof of concept or in a case report was
similar to the drug included in the orphan designation
application. This approach was needed to study both
rare diseases with and without an application for an
orphan designation in a similar way. This limitation
could be considered acceptable, with the assumption
that drug developers can learn from any experience with
drug candidates targeting low prevalence rare diseases.
Besides, the quality of the scientific output by disease
was not taken into account. Our study demonstrated
that for diseases first described before 1977 more orphan
designations have been requested than for diseases that
were first described after 1977. The quality of the scien-
tific output as well as the repetition of results may play a
role here and could be the subject of a follow-up study.
Finally, we have to note that due to the small sample size
in this study confidence intervals of relative risks were
wide. Nevertheless, the relative risks and their confidence
intervals derived from the (multivariate) regression ana-
lyses do identify the most relevant determinants of the
application of an orphan designation.
Overall conclusion and policy implications
The majority of low prevalence rare diseases remain
without therapy. This study shows that for low preva-
lence rare metabolic diseases preclinical proof of concept
of drug candidates and disease prevalence play an im-
portant role in the translation of disease knowledge into
an orphan drug development program. To effectively
expand drug development for low prevalence rare dis-
eases we recommend that incentives by public funders
and disease-focused foundations should (continue to)
aim at stimulating fundamental research to elucidate the
pathophysiology of the disease as well as the identification
of druggable targets and the testing of potential drug
candidates in a suitable preclinical model. Although not
exclusively, the latter represents an important incentive
for public or private partners to move a potential drugcandidate into the clinical development stage. More im-
portantly, an important hurdle will have been addressed
towards the ultimate goal: a therapy for a patient suffering
from a (low prevalence) rare disease.
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